RIGL Q2 2024 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M+37.0% YoY

Gross Profit

$34M92.4% margin

Operating Income

$447,0001.2% margin

Net Income

-$1M-2.8% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+24.7%

Cash Flow

Operating Cash Flow

$302,000

Free Cash Flow

$80,000

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$128M

Total Liabilities

$158M

Stockholders' Equity

-$30M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$27M	+37.0%
Gross Profit	$34M	$26M	+31.9%
Operating Income	$447,000	-$5M	+108.5%
Net Income	-$1M	-$7M	+84.4%

Revenue Segments

Gross product sales

$49M70%

Product sales, net

$33M48%

Revenues from collaborations

$3M5%

Discounts and allowances

-$16M-22%